X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CRS0540 is oral/IV antibacterial drug that intended for treatment of infections caused by antibiotic-resistant pathogens,derives from series of thiadiazole urea that exhibit potent inhibition of PolC, catalytic subunit of replicative DNA polymerase in Gram-positive bacteria.
Lead Product(s): CRS0540
Therapeutic Area: Infections and Infectious Diseases Product Name: CRS0540
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Praedicare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
CRS3123 represents a novel class of antibiotic and is not affected by resistance to any existing classes of antibiotics. It is a small molecule that selectively inhibits one form of the bacterial methionyl-tRNA synthetase enzyme.
Lead Product(s): CRS3123
Therapeutic Area: Infections and Infectious Diseases Product Name: CRS3123
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
Under this deal, Crestone’s drug candidate CRS0540 will be manufactured under GMP conditions, formulated for oral and intravenous administration, tested in IND-enabling safety pharmacology and GLP toxicity studies, and evaluated for safety in a first-in-human Phase 1 trial.
Lead Product(s): CRS0540
Therapeutic Area: Infections and Infectious Diseases Product Name: CRS0540
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $18.2 million Upfront Cash: Undisclosed
Deal Type: Funding July 01, 2020
Details:
Under this grant from NIH, Crestone’s drug candidate CRS3123 will be tested for pharmacokinetic properties and efficacy in an established preclinical model of H. pylori infection of the stomach.
Lead Product(s): CRS3123
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 27, 2020
Details:
Under this contract from CFF, efficacy of Crestone’s NTM drug candidate series will be tested at Colorado State University and Johns Hopkins University.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
